Thillard, Eve-Marie Gautier, Sophie Babykina, Evgeniya Carton, Louise Amad, Ali Bouzillé, Guillaume Beuscart, Jean-Baptiste Ficheur, Grégoire Chazard, Emmanuel
Published in
Frontiers in Pharmacology
Introduction Infliximab (IFX) was the first anti-tumor necrosis factor (TNFα) antibody to be used in the treatment of severe chronic inflammatory diseases, such as Crohn’s disease and rheumatoid arthritis. A number of serious adverse drug reactions are known to be associated with IFX use; they include infections, malignancies, and injection site re...
Burdett, Nikki Hsu, Kristin Xiong, Libo Tapia-Rico, Gonzalo Beckmann, Kerri Karapetis, Christos Brown, Michael P
Published in
Asia-Pacific journal of clinical oncology
To examine the cancer-specific outcomes for patients who experience immune-related adverse events requiring immunosuppression beyond corticosteroids. We performed a retrospective case series of patients between January 1, 2009 and April 1, 2018, across three metropolitan hospitals in Adelaide, South Australia. Eligible patients were identified from...
Bronswijk, Michiel; Moens, Annick; 117065; Lenfant, Matthias; Tops, Sophie; Compernolle, Griet; Van Assche, Gert; Vermeire, Severine; 3938; Gils, Ann; 5633; Ferrante, Marc; 45367;
BACKGROUND: The use of infliximab biosimilar CT-P13 has increased in patients with inflammatory bowel disease. Nevertheless, doubts about switching from infliximab originator to biosimilar still exist among patients and health care professionals. METHODS: Our tertiary referral center underwent a mandatory switch from infliximab originator to CT-P13...
Knyazev, Oleg Kagramanova, Anna Lischinskaya, Albina Korneeva, Irina Zvyaglova, Mariya Babayan, Anait Konoplyannikov, Anatoliy Parfenov, Asfold
Published in
Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.
The goal of the study was to compare the effect of combination therapy (local and systemic administration) with bone marrow mesenchymal stromal cells (MSC), anticytokine therapy with infliximab (IFX), and antibiotic (AB)/immunosuppressive (IS) therapy on the frequency of healing of simple perianal fistulas in Crohn’s disease. Three patient groups w...
Lu, Jiajing Li, Ying Yu, Ning Chen, Fujuan Ding, Yangfeng Yi, Xuemei
Published in
The Journal of International Medical Research
Juvenile generalized pustular psoriasis is a rare, severe type of psoriasis that can be life-threatening. Thus far, treatment for juvenile generalized pustular psoriasis has been challenging, and no standardized guidelines are available. Here, we describe two Chinese boys with juvenile generalized pustular psoriasis who were successfully treated wi...
Dovrolis, Nikolas Michalopoulos, George Theodoropoulos, George E. Arvanitidis, Kostantinos Kolios, George Sechi, Leonardo A. Eliopoulos, Aristidis G. Gazouli, Maria
Published in
Microorganisms
Even though anti-TNF therapy significantly improves the rates of remission in inflammatory bowel disease (IBD) patients, there is a noticeable subgroup of patients who do not respond to treatment. Dysbiosis emerges as a key factor in IBD pathogenesis. The aim of the present study is to profile changes in the gut microbiome and transcriptome before ...
Bouguen, Guillaume Huguet, Audrey Amiot, Aurélien Viennot, Stéphanie Cholet, Franck Nachury, Maria Flamant, Mathurin Reimund, Jean-Marie Desfourneaux, Véronique Boureille, Arnaud
...
Published in
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Few data are available on the effects of tumor necrosis factor (TNF) antagonist therapy for patients with internal fistulizing Crohn's disease (CD) and there is debate regarding the risk of abscess. We aimed to assess the long-term efficacy and safety of anti-TNF therapy for patients with internal fistulas. We performed a retrospective study of dat...
Kowalski, Tanya Mack, Heather G
Published in
Clinical & experimental optometry
Tumour necrosis factor alpha inhibitors are a relatively recent development and are becoming increasingly common in the management of many chronic inflammatory conditions such as rheumatoid arthritis, inflammatory bowel disease, ankylosing spondylitis and juvenile idiopathic arthritis. However, their ocular side effect profile is incomplete and poo...
Worland, Thomas Chin, Ken Lee van Langenberg, Daniel Garg, Mayur Nicoll, Amanda
Published in
Annals of Gastroenterology
Background Infliximab therapy may be associated with drug-induced liver injury (DILI), often resembling a drug-induced autoimmune hepatitis. However, the prevalence of DILI in patients receiving infliximab is unclear. Abnormal liver biochemistry is common in patients with inflammatory bowel disease (IBD) and definitive diagnosis may be difficult. T...
Szemes, Kata Soós, Alexandra Hegyi, Péter Farkas, Nelli Erős, Adrienn Erőss, Bálint Mezősi, Emese Szakács, Zsolt Márta, Katalin Sarlós, Patrícia
...
Published in
Frontiers in Medicine
Background: In steroid-refractory acute severe ulcerative colitis (ASUC), cyclosporine (CYS) or infliximab (IFX) may be considered as a second-line alternative to avoid colectomy. There are short-term data reported, but until now, there is no meta-analysis regarding long-term outcomes of CYS and IFX in patients with ASUC. Aim: To compare long-term ...
